A. Mirza

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).

Cellular Therapy Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma

Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel

Chimeric antigen receptor (CAR) T-cell therapy, including axicabtagene ciloleucel (axi-cel), is efficacious for older patients. However, patients aged 65 + are at risk for more severe neurotoxicity after infusion than younger patients, and post-infusion cognitive outcomes in older patients are unknown. This study asses...